BACKGROUND: Th EuroQol dimension (EQ-5D) is a widely used, standardised, quality of life measure producing health profildes, indices and states. OBJECTIVES: To assess how people with Multiple Sclerosis (MS) on delayed-release dimethyl fumarate (DMF; also known as gastro-resistant DMF) and prior approved interferon β-1a/b or glatiramer acetate (ABCRE) therapies rate their quality of life, based on responses to the EQ-5D. METHODS: Data were identified from the Adelphi MS Disease Specific Programme, a cross-sectional study of MS patients in five EU countries and the US. Relapsing Remitting MS (RRMS) patients were identified, receiving DMF or ABCRE therapies with treatment duration greater than 12 months. General HRQoL was evaluated using the EQ-5D 3 level utility score, a standardized instrument providing a simple, generic measure of health, consisting of 5 questions measuring dimensions of health states (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). A visual analog scale (VAS) is also included to measure overall health. Inverse-probability-weighted regression-adjustment estimated average treatment effects (ATEs) on the EQ-5D across DMF and ABCRE cohorts, utilizing a propensity score generated from age, gender, EDSS score at current treatment initiation, BMI,  duration of current treatment, line of therapy, time since MS diagnosis, and number of comorbid conditions. RESULTS: A total of 258 (30 DMF, 228 ABCRE) patients completed the EQ-5D questionnaire (mean age, 37.4 years; 31% male) with a mean time since diagnosis of 5.57 years. There was a significant difference in the EQ-5D utility score between the DMF and ABCRE cohorts (ATE: +0.075, p=0.016, vs. 0.82 for ABCRE). Similarly, the overall VAS health reported by patients in the DMF cohort was significantly higher than the ABCRE cohort (ATE: +10.84, p<0.001, vs 74.55 for ABCRE). CONCLUSIONS: Patients on DMF reported significantly better functioning and quality of life compared with ABCRE patients, as measured by the EQ-5D.